本文選題：受體　切入點：白細(xì)胞介素　出處：《中國新藥與臨床雜志》2017年05期

【摘要】：白細(xì)胞介素17(IL-17)家族在銀屑病的發(fā)病過程中發(fā)揮重要作用,IL-17A受體拮抗劑能夠抑制IL-17的活性。布羅達(dá)單抗為一種人源化免疫球蛋白G抗體,對IL-17A受體具有較高的親和力,能夠抑制IL-17所致的炎癥反應(yīng),在日本已經(jīng)被批準(zhǔn)用于銀屑病的治療。患者對布羅達(dá)單抗具有較好的耐受性,最常見的不良事件主要包括鼻咽炎、腹瀉、上呼吸道感染等。
[Abstract]:Interleukin 17 (IL-17) family play an important role in the pathogenesis of psoriasis, IL-17A receptor antagonists can inhibit the activity of IL-17. Broda a humanized monoclonal antibody for immunoglobulin G antibodies with high affinity for IL-17A receptor can inhibit the inflammatory reaction caused by IL-17, has been in Japan approved for the treatment of psoriasis. Patients have good tolerance to Broda mAb, the most common adverse events including nasopharyngitis, diarrhea, upper respiratory tract infection.

【作者單位】： 臨沂市中心醫(yī)院藥學(xué)部;
【分類號】：R986

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 仇s，

本文編號：1695507